JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice TargetHot
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.